NCT02690714View on ClinicalTrials.gov

A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 4, 2016

Primary Completion Date

December 17, 2017

Study Completion Date

October 8, 2018

Conditions
HypoplasminogenemiaCongenital Plasminogen Deficiency
Interventions
BIOLOGICAL

Plasminogen (Human) intravenous

Prometic Plasminogen (Human) intravenous infusion given as single dose of 6.6 mg/kg in Segment 1 and repeat doses in Segments 2 and 3.

Trial Locations (2)

46260

Indiana Hemophilia and Thrombosis Center, Indianapolis

0372

Oslo University Hospital HF, Oslo

All Listed Sponsors
lead

Prometic Biotherapeutics, Inc.

INDUSTRY

NCT02690714 - A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia | Biotech Hunter | Biotech Hunter